No End to the Dow's Triple-Digit Win Streak

Wall Street's bounce back from last week continues today, with the Dow Jones Industrial Average (DJINDICES: ^DJI  ) looking to continue its recent run of triple-digit moves. The blue-chip index is up 110 points as of 2:25 p.m. EDT after earlier soaring more than 150 points, pushing back above the 15,000 mark. Most Dow stocks are in the green today after positive consumer and housing data lifted investor optimism. How is this affecting your portfolio? Let's check out the stories you need to know about today.

More signs of the economy's rise
The National Association of Realtors kicked things off today by reporting that pending home sales jumped to a six-year high in May. Housing's rebound has accelerated the economy's rise, and signs are still pointing up. Separately, the Department of Commerce reported today that consumer spending rose 0.3% in May after contracting in April -- a positive sign, considering that income rose by an even better 0.5% in May. While the U.S. economy has grown more slowly than expected -- first-quarter GDP was revised down to 1.8% from an earlier estimate of 2.4% -- consumers are returning to the markets, and that's pivotal if the U.S. is to continue recovering from the recession.

Among individual stocks, American Express (NYSE: AXP  ) has risen 1.6% to rank among the Dow's leaders. More than 50% of the firm's revenue comes from the U.S., and an improving economy and growing consumer spending will mean big things for the company's top line in the future. Although American Express has historically appealed to more affluent consumers -- a group that can weather downturns like the recession with less difficulty -- the economy's comeback and the market's gains over the past few years have nonetheless helped this firm greatly.

Big pharma Pfizer (NYSE: PFE  ) is also on the upswing today, rising 1.4%. The company finally resolved asbestos-related claims against Quigley, a company it has owned since the 1960s, when a federal judge signed off on a plan that will have Pfizer paying $964 million to settle the claims. It's a pricey sum for Pfizer, but the resolution will allow the company to move on -- and it's not as if Pfizer doesn't have a strong financial base. While the company has been hit by losses relating to patent expirations, like most Big Pharma firms, Pfizer's strong and diverse pipeline will boost the company's sales for years to come. A $964 million settlement won't sting for long.

Finally, Boeing (NYSE: BA  ) is up 2.4%, leading today's Dow run. The company's joint space-launch venture with Lockheed-Martin (NYSE: LMT  ) , United Launch Alliance, won a $1.1 billion contract from the Department of Defense Wednesday in a new award for the Pentagon's ongoing Evolved Expendable Launch Vehicle program. The ULA has been a successful push by Lockheed and Boeing into the space industry, which is heating up as private contractors take up much of the launch work once done by government entities. While Boeing and Lockheed still derive most of their revenue from aircraft and military contracts, this is a promising and exciting area for investors to keep an eye on. It won't make or break either firm's business, but it can ease the pain of problems such as Boeing's 787 grounding and sequestration's defense cuts.

The best Dow stocks for income investors
Dow picks like Pfizer deliver a strong dividend for income investors, but which blue-chip stocks are the best at paying out consistent yields? If you're looking for some long-term investing ideas, you're invited to check out The Motley Fool's brand-new special report, "The 3 Dow Stocks Dividend Investors Need." It's absolutely free, so simply click here now and get your copy today.


Read/Post Comments (2) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 27, 2013, at 3:51 PM, EllenBrandtPhD wrote:

    Big potential news for PFE within two weeks is whether it or rival bidder AMGN will win the battle for very well-regarded Russian firm Biocad.

    Then there's the question of whether investors and traders will reward or not reward whichever of the two companies wins the bid, which depends largely on the price.

    Because Russia and Russian shares and Russian currency are under such pressure lately, most gurus seem to think whoever wins the bid will get an immense bargain and that the Street will like it.

    Which of the two companies wins the bidding war is still a toss-up, however. AMGN wants it more. But PFE has deeper pockets. In fact, PFE's pockets are so deep now, it could possibly buy Russia, the country.

  • Report this Comment On June 27, 2013, at 3:56 PM, EllenBrandtPhD wrote:

    For Traders, PFE could be a nice buy prior to end of month, end of quarter tomorrow.

    My reasoning is that because of the TOTAL misinterpretation by some Momo players of that "guidance" early in the week, the stock is lagging its fellow Dow components on a weekly basis.

    And the Shorts here are not all that strong, IMO, more opportunistic than conviction-Shorts.

    Ergo, a possible rally tomorrow, after the failed attempt at one today.

    Biocad will be a factor next week, but probably not tomorrow, although anyone not pure daytrading has it on their radar.

Add your comment.

DocumentId: 2513625, ~/Articles/ArticleHandler.aspx, 7/29/2014 1:26:06 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement